Specifically, during the establishment of Cytarabine-resistant AML sublines, we identified a novel mechanism of stable dCK inactivation via introduction of a 5 bp genomic deletion resulting in a frameshift, hence provoking dCK transcript degradation via NMD. The gene discussed is DCK; the disease is acute myeloid leukemia.